Literature DB >> 29388837

Adenovirus Lacking E1b Efficiently Induces Cytopathic Effect in HPV-16-Positive Murine Cancer Cells via Virus Replication and Apoptosis.

Elvis Martinez-Jaramillo1,2, Rodolfo Garza-Morales1,2, Stephen L Wechman1, Roberto Montes de Oca-Luna2, Odila Saucedo-Cardenas2,3, Haval Shirwan4, Esma Yolcu4, Kelly M McMasters1,5, Jorge G Gomez-Gutierrez1,5.   

Abstract

Conditionally replicative adenoviruses (CRAds) replicate poorly in murine cancer cells; however, E1b-deleted CRAds may replicate effectively in HPV16-E6/E7-positive murine cancer cells (TC-1). The HPV16 E7 open reading frame encodes functions analogous to these deleted adenovirus E1 proteins. In this study, an E1b-deleted CRAd (Adhz60) was evaluated for its ability to replicate and induce oncolysis in TC-1 cells. Adhz60-mediated oncolysis was similar in TC-1 and HeLa cells. Productive viral replication was evident based on expression of E1A and hexon, production of infectious virus progeny, and Adhz60-induced apoptosis. The results suggest that TC-1 murine cancer cells allow Adhz60 replication and oncolysis.

Entities:  

Keywords:  Adenovirus; Apoptosis; HPV16; Oncolysis; Replication

Mesh:

Substances:

Year:  2018        PMID: 29388837      PMCID: PMC6088374          DOI: 10.1080/07357907.2018.1430812

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  20 in total

1.  Treating tumors with a vaccinia virus expressing IFNβ illustrates the complex relationships between oncolytic ability and immunogenicity.

Authors:  Liang-Chuan S Wang; Rachel C Lynn; Guanjun Cheng; Edward Alexander; Veena Kapoor; Edmund K Moon; Jing Sun; Zvi G Fridlender; Stuart N Isaacs; Stephen H Thorne; Steven M Albelda
Journal:  Mol Ther       Date:  2011-10-18       Impact factor: 11.454

2.  Establishment of a mouse melanoma model system for the efficient infection and replication of human adenovirus type 5-based oncolytic virus.

Authors:  Sujin Kang; Joo-Hang Kim; So Young Kim; Dongxu Kang; Suyeon Je; Jae J Song
Journal:  Biochem Biophys Res Commun       Date:  2014-10-01       Impact factor: 3.575

3.  Enhanced cancer cell killing by truncated E2F-1 used in combination with oncolytic adenovirus.

Authors:  Jorge G Gomez-Gutierrez; Xiao-Mei Rao; Heshan Sam Zhou; Kelly M McMasters
Journal:  Virology       Date:  2012-09-27       Impact factor: 3.616

4.  Effect of adenovirus-mediated heat shock protein expression and oncolysis in combination with low-dose cyclophosphamide treatment on antitumor immune responses.

Authors:  Nelson C Di Paolo; Sebastian Tuve; Shaoheng Ni; Karl Erik Hellström; Ingegerd Hellström; André Lieber
Journal:  Cancer Res       Date:  2006-01-15       Impact factor: 12.701

5.  Human papilloma virus E6 and E7 proteins support DNA replication of adenoviruses deleted for the E1A and E1B genes.

Authors:  D S Steinwaerder; C A Carlson; A Lieber
Journal:  Mol Ther       Date:  2001-09       Impact factor: 11.454

Review 6.  Oncolytic viruses: adenoviruses.

Authors:  Julia Niemann; Florian Kühnel
Journal:  Virus Genes       Date:  2017-07-12       Impact factor: 2.198

7.  Novel immunocompetent murine tumor models for the assessment of replication-competent oncolytic adenovirus efficacy.

Authors:  Gunnel Halldén; Richard Hill; Yaohe Wang; Arthi Anand; T-Chiang Liu; Nick R Lemoine; Jennelle Francis; Lynda Hawkins; David Kirn
Journal:  Mol Ther       Date:  2003-09       Impact factor: 11.454

Review 8.  The papillomavirus E7 proteins.

Authors:  Ann Roman; Karl Munger
Journal:  Virology       Date:  2013-05-31       Impact factor: 3.616

9.  The human papillomavirus type 16 E7 gene encodes transactivation and transformation functions similar to those of adenovirus E1A.

Authors:  W C Phelps; C L Yee; K Münger; P M Howley
Journal:  Cell       Date:  1988-05-20       Impact factor: 41.582

10.  A novel immunocompetent murine model for replicating oncolytic adenoviral therapy.

Authors:  L Zhang; F Hedjran; C Larson; G L Perez; T Reid
Journal:  Cancer Gene Ther       Date:  2014-12-19       Impact factor: 5.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.